VC-backed Beam Therapeutics debuts IPO

Cambridge, Massachusetts-based Beam Therapeutics, a developer of precision genetic medicines, has raised about $180 million for its IPO after pricing its over 10 million shares at $17 per share.

6 February 2020•2 mins read
Feature image
LinkedInXEmail
LinkedInXEmail